In November 2025, Epicrispr Biotechnologies Inc. announced a clinical trial is to learn how safe and tolerable EPI-321 is and ...
DelveInsight’s, “Spinal Muscular Atrophy Pipeline Insight 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal muscular atrophy pipeline landscape. It ...
Opportunities in the SMA market include leveraging the launch of new myostatin inhibitors, expanding Zolgensma formulations to increase patient eligibility, and capitalizing on cheap nusinersen ...
Emmes today announced that Casimir’s research on the development of the Duchenne Video Assessment (DVA) scorecards was published in PLOS ONE. Emmes acquired Casimir in March 2022, and the group is now ...
Dublin, July 29, 2024 (GLOBE NEWSWIRE) -- The "Spinal Muscular Atrophy: Opportunity Assessment and Forecast 2023-2033" report has been added to ResearchAndMarkets.com's offering. The diagnosed ...
"Duchenne Muscular Dystrophy Pipeline Analysis"DelveInsight's, "Duchenne Muscular Dystrophy - Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs ...
Understanding individual muscle strength is crucial for optimizing physical therapy and enhancing athletic performance. Traditional methods, however, often fall short in precision. The newly ...
Muscular endurance tests can help you gauge the effectiveness of your workout and provide clues about your overall physical fitness. When it comes to measuring progress in the weight room, muscular ...
Risdiplam may provide benefit for patients suffering from SMA type 1 and there is no added benefit of onasemnogene abeparvovec for any type. Risdiplam and onasemnogene abeparvovec may offer an added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback